ClinicalTrials.gg
RecruitingNCT07260474CALAMBREUpdated Oct 7, 2026

Comparison of the Amplatzer Amulet Versus LAmbre Device for Left Atrial Appendage Closure

An interventional study of Patients implanted with Amplatzer Amulet™ and Patients implanted with LAmbre™ in Coronary Artery Disease, sponsored by Fundación EPIC. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Fundación EPIC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled May 2024, registered Nov 2025).
  • Started May 2024; still recruiting 2 years 6 months later.
Updated Oct 7, 2026Now RecruitingFirst site in Spain+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies in Coronary Artery Disease by Fundación EPIC — 13 open to participants now, 20 under way, none of them phase 3. Coronary Artery Disease · Fundación EPIC.

Planned enrollment
6th of 13
200 · median 200
Started
2024
with 5 others
No phase
11 of 33
7 open now
Primary completion
2026-12
later than 5 of 19 live
Registered
31st of 33
by date

Among the 33 studies in Coronary Artery Disease by Fundación EPIC, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is one of 6 that started in 2024, is one of 11 with no phase, reaches primary completion later than 5 of the 19 other live ones, and was the 31st registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

13 of the 33 studies in Coronary Artery Disease by Fundación EPIC are open now, in 7 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Coronary Artery Disease by Fundación EPIC, or all of them as a file.
02

Study summary

Clinical investigation with CE-marked medical devices, multicenter, prospective, randomized and controlled. Patients with non-valvular atrial fibrillation at high embolic risk and with at least one high bleeding risk criterion according to the Munich consensus document will be randomized to left atrial appendage closure with either the Amplatzer Amulet™ or the LAmbre™ device. The study is designed to compare the efficacy and safety of both devices regarding successful implantation, effective appendage closure, and clinical outcomes at follow-up.

Read the detailed description

Clinical investigation with CE-marked medical devices, multicenter, prospective, randomized and controlled. Patients with non-valvular atrial fibrillation at high embolic risk and with at least one high bleeding risk criterion according to the Munich consensus document will be randomized to left atrial appendage closure with either the Amplatzer Amulet™ or the LAmbre™ device. The study is designed to compare the efficacy and safety of both devices regarding successful implantation, effective appendage closure, and clinical outcomes at follow-up.

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(MUST MEET ALL INCLUSION CRITERIA)

  • Patient with aged ≥18 years AND;
  • Patient have non-valvular atrial (NVAF) with a CHA2DS2-VASc score ≥2, and presented at least one high-bleeding-risk criterion according to the Munich consensus document AND;
  • Patient are required to undergo preprocedural TEE / CCTA to confirm the absence of LAA thrombus and to ensure that LAA anatomy is suitable for closure with either device.
  • Patient who has been informed of the characteristics of the study and has provided written ..

Exclusion criteria

Exclusion Criteria:

(MUST NOT MEET ANY EXCLUSION CRITERIA)

  • Patient \<1 year (terminal illness).
  • Patient with requirement for oral anticoagulation therapy for any indication other than non-valvular atrial fibrillation.
  • Patient with prior surgical ligation or obliteration of the left atrial appendage.
  • Patient with history of allergic reaction or intolerance to any material used in the study devices or to any of the antithrombotic agents required post-procedure.
  • Patient with active systemic infection.
  • Patient with concurrent participation in another study that may affect study results.
  • Patient with inability or unwillingness to comply with the study protocol or follow-up requirements.
  • Patient pregnant or breastfeeding women.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    Amplatzer Amulet™left atrial appendage occluder

    Device: Patients implanted with Amplatzer Amulet™

  • Other
    LAmbre™left atrial appendage occluder

    Device: Patients implanted with LAmbre™

Interventions

  • DevicePatients implanted with Amplatzer Amulet™

    Left atrial appendage closure with the Amplatzer Amulet™ device. The procedure will be performed according to standard practice using the manufacturer's instructions for use.

  • DevicePatients implanted with LAmbre™

    Left atrial appendage closure with the LAmbre™ device. The procedure will be performed according to standard practice using the manufacturer's instructions for use.

06

What researchers measure

Primary outcomes

  1. EFFICACY: Device success

    Percentage Device success defined as: Successful deployment and stable implantation of the assigned device within the left atrial appendage during the index procedure and no crossover to the alternative device and effective closure of the appendage with a residual leak ≤5 mm as assessed by TEE(Transesophageal Echocardiography) or CCTA (Cardiac Computed Tomography Angiography) at 90 days.

    Time frame: 3 months

Secondary outcomes

  1. SAFETY: Clinical success

    Percentage of Device success plus absence of all-cause mortality, stroke, systemic embolism, or procedure-related complications at 90 days.

    Time frame: 3 months

  2. SAFETY: Procedure-related complications

    Percentage of Composite of death, stroke, systemic or pulmonary embolism, air embolism, any bleeding, pericardial effusion, vascular access complication, device-related complication, or AKI (Acute Kidney Injury) within 7 days (or later if related to the procedure).

    Time frame: 7 days

  3. EFFICACY: Residual leak

    Percentage of residual leak \>5 mm as assessed by TEE or CCTA (core lab evaluation).

    Time frame: 3 months

  4. EFFICACY: Residual leak

    Percentage of residual leak \>5 mm as assessed by TEE or CCTA (core lab evaluation).

    Time frame: 12 months

  5. SAFETY:Device-related thrombus (DRT)

    Percentage of Homogeneous mass (TEE) or hypoattenuated thickening (CCTA) on the atrial surface of the device, adjudicated by independent imaging experts.

    Time frame: 3 months

  6. SAFETY: MACE

    Percentage of Composite of all-cause mortality, cardiovascular mortality, ischemic or hemorrhagic stroke, systemic embolism, pulmonary embolism, myocardial infarction, and bleeding (classified by BARC (Bleeding Academic Research Consortium)).

    Time frame: 3 months

  7. SAFETY: MACE

    Percentage of Composite of all-cause mortality, cardiovascular mortality, ischemic or hemorrhagic stroke, systemic embolism, pulmonary embolism, myocardial infarction, and bleeding (classified by BARC (Bleeding Academic Research Consortium)).

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Landmesser U, Skurk C, Tzikas A, Falk V, Reddy VY, Windecker S. Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives. Eur Heart J. 2024 Aug 21;45(32):2914-2932. doi: 10.1093/eurheartj/ehae398. PubMed 39027946 ↗
  • Lakkireddy D, Ellis CR, Thaler D, Swarup V, Gambhir A, Hermiller J, Nielsen-Kudsk JE, Worthley S, Nair D, Schmidt B, Horton R, Gupta N, Anderson JA, Zhao H, Alkhouli M, Windecker S. 5-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial. J Am Coll Cardiol. 2025 Mar 25;85(11):1141-1153. doi: 10.1016/j.jacc.2024.10.101. Epub 2024 Nov 18. PubMed 39570242 ↗
  • Alkhouli M, Freeman JV, Ellis CR, Shah AP, Gada H, Coylewright M, Lo M, Makkar A, Agarwal H, Lakkireddy D. First Experience With Amulet in the United States: Early Insights From EMERGE LAA Postapproval Study. JACC Cardiovasc Interv. 2024 Jan 19:S1936-8798(23)01553-4. doi: 10.1016/j.jcin.2023.11.027. Online ahead of print. PubMed 38310499 ↗
  • Bangash AB, Li Y, Huang W, Zhong J, Zheng H, Zhang D, Zeng A, Wang R, Zhao W, Wang M, Zhao Y, Yu L, Liu Q, Jiang R, Jiang C, Zhang J. Left atrial appendage occlusion using the LAmbre device in atrial fibrillation patients with a history of ischemic stroke: 1-Year outcomes from a multicenter study in China. Pacing Clin Electrophysiol. 2023 Dec;46(12):1478-1483. doi: 10.1111/pace.14866. Epub 2023 Nov 9. PubMed 37943004 ↗
  • Samaras A, Papazoglou AS, Balomenakis C, Bekiaridou A, Moysidis DV, Patsiou V, Orfanidis A, Giannakoulas G, Kassimis G, Fragakis N, Saw J, Landmesser U, Alkhouli MA, Tzikas A. Residual leaks following percutaneous left atrial appendage occlusion and outcomes: a meta-analysis. Eur Heart J. 2024 Jan 14;45(3):214-229. doi: 10.1093/eurheartj/ehad828. PubMed 38088437 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 31 months is close to that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → May 2024, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 3, 2025
StartActual
May 5, 2024was Jan 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 7, 2026
Sites
1 site added — first site in Spain
Show site
  • Hospital Universitario La Paz · Fuencarral-El Pardo, Spain
Oct 7, 2026
Start date
Jan 30, 2026→May 5, 2024 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Spain
    Show site
    • Hospital Universitario La Paz · Fuencarral-El Pardo, Spain
    Start date Jan 30, 2026→May 5, 2024 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07260474
Lead sponsor
Fundación EPIC
Responsible party
Sponsor
First posted
Dec 3, 2025
Start date
May 5, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

BORJA Rivero-Santana, MD, PhD
Contact
borja.riversa@gmail.com
0034696170677
FUNDACION EPIC
Contact
iepic@fundacionepic.org
0034987876135

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion